Phio Pharmaceuticals’ (PHIO) “Buy” Rating Reaffirmed at HC Wainwright

Phio Pharmaceuticals (NASDAQ:PHIO)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $14.00 price target on the stock.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Phio Pharmaceuticals in a report on Friday, July 17th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Phio Pharmaceuticals has a consensus rating of “Hold” and an average price target of $14.00.

Phio Pharmaceuticals Stock Performance

PHIO stock opened at $1.19 on Wednesday. Phio Pharmaceuticals has a 52-week low of $0.81 and a 52-week high of $4.19. The company has a market capitalization of $13.83 million, a P/E ratio of -0.92 and a beta of 0.82. The business has a 50-day simple moving average of $1.05 and a two-hundred day simple moving average of $1.13.

Phio Pharmaceuticals (NASDAQ:PHIO) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.36). As a group, sell-side analysts forecast that Phio Pharmaceuticals will post -1.41 earnings per share for the current fiscal year.

Institutional Trading of Phio Pharmaceuticals

A hedge fund recently raised its position in Phio Pharmaceuticals stock. Geode Capital Management LLC grew its holdings in shares of Phio Pharmaceuticals Corp. (NASDAQ:PHIO) by 60.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 92,638 shares of the company’s stock after buying an additional 34,732 shares during the quarter. Geode Capital Management LLC owned 0.86% of Phio Pharmaceuticals worth $97,000 at the end of the most recent reporting period. 57.31% of the stock is owned by institutional investors and hedge funds.

About Phio Pharmaceuticals

Phio Pharmaceuticals, Inc (NASDAQ: PHIO) is a clinical‐stage biotechnology company focused on the discovery and development of dual RNA interference (RNAi) therapeutics. Utilizing its proprietary Transitional RNAi (TRiMTM) platform, Phio aims to simultaneously silence multiple gene targets to achieve enhanced therapeutic activity. The company’s core mission is to advance next‐generation RNAi compounds with potential applications in oncology and immuno‐oncology.

Phio’s TRiMTM platform is designed around the delivery of synthetic, double‐stranded RNA duplexes that can be engineered to target specific combinations of genes implicated in tumor growth and immune evasion.